Xbiotech’s potential upside vs. downside
Xbiotech (NASDAQ:XBIT) has presented the abstract of its European Phase III trial of Xilonix to treat patients with metastatic colorectal cancer (mCRC) refractory to standard treatment at the ESMO GI (European Society for Medical Oncology) 2016, early July. The abstract has shown a 76% relative increase in clinical response rate (CRR), associated with a 2.7-fold increase in median overall survival (11.5 vs. 4.2 months responders vs. non-responders), an increase in Lean Body Mass (LBM) and an improved Quality of Life (QoL) with little safety concerns, all surrogate parameters for anti-cancer activity and prolonged survival – see ESMO Press release and my previous SA article.
This abstract came under scrutiny by the discussant, an executive member of the ESMO, at the same conference, questioning whether those results “is any benefit in translating this trial into practice.” – press release ESMO .
Others, like Adam Feuerstein, right away played on the above criticism, taking down Xbiotech’s results – see here, here. In my opinion I still do not have an explanation on how Adam Feuerstein was able to tweet about the OS data before those were presented, other than receiving it from an insider. His tweet was made one day before the scheduled presentation that the Congress – see agenda to compare. In addition, neither on the presentation slide nor on the press release of the discussant issued by ESMO was a declaration of conflict of interest. It goes without saying that the discussant- obviously together with another colleague and executive director of ESMO – are biased towards Xbiotech and Xilonix. Both were prominent figures in clinical trials of Regorafenib and Lonsurf (trifluridine/tipiracil), currently the only two drugs approved for last-line treatment in mCRC refractory to standard therapy. In my opinion such a bias should have been declared. Furthermore, the discussant held several positions with big pharmaceuticals, including Regorafenib’s Bayer AG (OTCPK:BAYZF, OTCPK:BAYRY)- see CME information from Medscape.
Best Medical Stocks To Own For 2018: Syngenta AG(SYT)
- [By WWW.THESTREET.COM]
Syngenta AG (SYT) CEO Erik Fyrwald said Wednesday that he was “entirely confident” the company’s $43 billion takeover by China National Chemical Corp. would close in the second quarter of this year and dismissed suggestions it would be disrupted by a third party.
- [By Shanthi Rexaline]
Agri-Input Companies — Seeds/ Fertilizers/Pesticides Manufacturers
Monsanto Company (NYSE: MON): +68.82 percent since 2011. Syngenta AG (ADR) (NYSE: SYT): +56.26 percent since 2011. Mosaic Co (NYSE: MOS): -63.1 percent since 2011. Potash Corporation of Saskatchewan (USA) (NYSE: POT): -67.8 percent since 2011. CF Industries Holdings, Inc. (NYSE: CF): +5.04 percent since 2011. Agrium Inc. (USA) (NYSE: AGU): +1.10 percent since 2011.
Best Medical Stocks To Own For 2018: IDT Corporation(IDT)
- [By Lisa Levin]
IDT Corporation (NYSE: IDT) was down, falling around 15 percent to $15.88 following Q2 results. IDT reported fiscal second-quarter earnings of $875,000.
Best Medical Stocks To Own For 2018: 2U, Inc.(TWOU)
- [By David Kretzmann]
Since its IPO in March 2014, 2U (NASDAQ:TWOU) stock is up over 160% as the company forges partnerships with famous schools, including Georgetown, Yale, Berkeley, and New York University.
Best Medical Stocks To Own For 2018: Open Text Corporation(OTEX)
- [By WWW.MONEYSHOW.COM]
One split announcement came from OpenText Inc. (OTEX) — a stock we had already added to our portfolio back in July, 2014; it has since done very well.
Best Medical Stocks To Own For 2018: Progressive Corporation (PGR)
- [By Chris Lange]
Progressive Corp. (NYSE: PGR) is set to report its third-quarter results Tuesday morning as well. The analysts consensus estimates are $0.36 in EPS on revenue of $6.99 billion. Shares were changing hands at $48.67 on Fridays close. The consensus price target is $49.07, and the 52-week range is $30.99 to $49.75.